IR Notice
27 July 2021
Dear Investors, This is John Rim CEO of Samsung Biologics.
- Q2'21 Key Highlights
-
- Q2 Earnings - Revenue KRW 412.2B - OP KRW 166.8B
- Moderna DP CMO Contract
- mRNA DS Expansion
- Sustainability Report lssued
Today Samsung Biologics announced our 2021 Q2 earnings.
Samsung Biologics recorded 412.2 bilion won in revenue and 166.8 bilion won in operating profit, due to sales volume increase attributable to stable operation of Plants 1&2 and increasing utilization of Plant 3. Driven by new contracts in 2020 and increased orers of existing contracts, overall sales grew by 104.5 bilion won, and operating profit increased by 85.7 bilion won compared to the same period last yera.
We credit these great results to our core values and outstanding business execution in turning a crisis into an opportunity by leveraging our well-prepared system amid the challenging COVID-19 environment.
"Drive. For Life."
In May, Samsung Biologics became the first partner with Moderna in Asia with the drug product manufacturing contract of their COVID-19 vaccine. Subsequently we also announced our plan to add an mRNA vaccine drug substance facility by 2022 in order to provide a full end-toend service for mRNA vaccine production from drug substance manufacturing to aseptic fill and finish with labeling, packaging, and cold storage. We hope that with this expansion of our services portfolio, Samsung Biologics will provide an even greater contribution to the rapid supply of high-quality vaccines worldwide.
We will also continue to study new technologies such as cell and gene therapies in addition to mRNA to secure new platforms for growth and business momentum.
Plant 4 Expansion
Currently Plant 4 is on track to begin partial GMP operations by the end of 2022. As global biopharmaceutical companies broaden and diversify their SCM strategy with new antibody drugs continuously under development, the demand for CDMOs is steadily increasing. This need for additional capacity is not only reflected in our Plant 4 pre-sales activity, but is also driving us to closely review the investment and construction of a second bio-campus in Songdo, Incheon.
3-Dimensional Expansion : Capacity / Geography / Portfolio
Earlier this yera, we shared our '3-Dimensional Expansion' strategy to becoming a fully integrated global top-tier biopharmaceutical company, and I am proud to confirm we are keeping that promise even at this moment.
In addition, Samsung Biologics will be proactive in fulfilling our commitment and responsibility to a better planet and social environment as signaled by the issuance of our first annual sustainability report during this past quarter. We will also continue to stay ahead of and respond to evolving market dynamics and client needs to maximize corporate and shareholder value.
Thank you for your continued support.
Sincerely, John Rim
President and CEO, Samsung Biologics
27 July 2021
Dear Investors, This is John Rim CEO of Samsung Biologics.
- Q2'21 Key Highlights
-
- Q2 Earnings - Revenue KRW 412.2B - OP KRW 166.8B
- Moderna DP CMO Contract
- mRNA DS Expansion
- Sustainability Report lssued
Today Samsung Biologics announced our 2021 Q2 earnings.
Samsung Biologics recorded 412.2 bilion won in revenue and 166.8 bilion won in operating profit, due to sales volume increase attributable to stable operation of Plants 1&2 and increasing utilization of Plant 3. Driven by new contracts in 2020 and increased orers of existing contracts, overall sales grew by 104.5 bilion won, and operating profit increased by 85.7 bilion won compared to the same period last yera.
We credit these great results to our core values and outstanding business execution in turning a crisis into an opportunity by leveraging our well-prepared system amid the challenging COVID-19 environment.
"Drive. For Life."
In May, Samsung Biologics became the first partner with Moderna in Asia with the drug product manufacturing contract of their COVID-19 vaccine. Subsequently we also announced our plan to add an mRNA vaccine drug substance facility by 2022 in order to provide a full end-toend service for mRNA vaccine production from drug substance manufacturing to aseptic fill and finish with labeling, packaging, and cold storage. We hope that with this expansion of our services portfolio, Samsung Biologics will provide an even greater contribution to the rapid supply of high-quality vaccines worldwide.
We will also continue to study new technologies such as cell and gene therapies in addition to mRNA to secure new platforms for growth and business momentum.
Plant 4 Expansion
Currently Plant 4 is on track to begin partial GMP operations by the end of 2022. As global biopharmaceutical companies broaden and diversify their SCM strategy with new antibody drugs continuously under development, the demand for CDMOs is steadily increasing. This need for additional capacity is not only reflected in our Plant 4 pre-sales activity, but is also driving us to closely review the investment and construction of a second bio-campus in Songdo, Incheon.
3-Dimensional Expansion : Capacity / Geography / Portfolio
Earlier this yera, we shared our '3-Dimensional Expansion' strategy to becoming a fully integrated global top-tier biopharmaceutical company, and I am proud to confirm we are keeping that promise even at this moment.
In addition, Samsung Biologics will be proactive in fulfilling our commitment and responsibility to a better planet and social environment as signaled by the issuance of our first annual sustainability report during this past quarter. We will also continue to stay ahead of and respond to evolving market dynamics and client needs to maximize corporate and shareholder value.
Thank you for your continued support.
Sincerely, John Rim
President and CEO, Samsung Biologics